Akarna Therapeutics' Series B Round

Akarna Therapeutics raised a round of funding on February 16, 2016.

Akarna Therapeutics develops novel small molecule therapeutics that target inflammatory and fibrotic diseases. Its lead program is a FXR agonist for the treatment of non-alcoholic steatohepatitis (NAS…

Articles about Akarna Therapeutics' Series B Round: